质子泵抑制剂治疗与化脓性肝脓肿患者死亡率升高相关
该回顾性分析纳入2005年1月至2017年3月间的181例化脓性肝脓肿患者,比较接受与未接受质子泵抑制剂(PPI)治疗者的索引死亡率。
要点
- 181例化脓性肝脓肿患者中,100例(55.2%)接受PPI治疗,81例(44.8%)未接受。
- PPI组索引死亡率为30.0%,未接受PPI组为11.1%,差异有统计学意义(P=0.003)。
核心结论
- 在化脓性肝脓肿患者中,PPI治疗与较高的索引死亡率相关。
- 作者认为,对化脓性肝脓肿高危患者应批判性评估PPI治疗的指征。
研究设计与样本
- 回顾性分析,纳入2005年1月至2017年3月间181例化脓性肝脓肿患者。
- 查阅医疗记录,包括PPI治疗、微生物学和影像学数据。
- 主要终点为索引死亡率,采用单因素和多因素逻辑回归模型分析预测因素。
主要发现
- 100例(55.2%)接受PPI治疗,81例(44.8%)未接受PPI治疗。
- 两组中最常见的病原体均为肠球菌属和咽峡炎链球菌群。
- PPI治疗组索引死亡率为30.0%,未接受PPI治疗组为11.1%,差异有统计学意义(P=0.003)。
关键数值与推荐
- PPI治疗组索引死亡率30.0% vs 未接受PPI治疗组11.1%(P=0.003)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Proton pump inhibitors (PPI) are often used in patients with gastro-esophageal reflux and peptic ulcer disease. A higher risk for infectious diseases and for pyogenic liver abscess has been reported in patients with prolonged PPI intake. Although many patients have ongoing PPI treatment after diagnosis of liver abscess, there are no data available that focus on the prognostic impact of PPI treatment in these patients. AIM: To analyse the effect of PPI treatment on mortality in patients with pyogenic liver abscesses. METHODS: Between January 2005 and March 2017, one hundred and eighty-one patients with pyogenic liver abscess were retrospectively included in this analysis. Medical records including PPI treatment, microbiological and imaging data were reviewed. The primary endpoint was index mortality and predictive factors were analysed using uni- and multivariate logistic regression models. RESULTS: One hundred patients with pyogenic liver abscess (55.2%) were treated with PPI compared to 81 patients (44.8%) without PPI treatment. In both patient cohorts, enterococcus spp. and streptococcus of the anginous group were the most common pathogens identified. Patients with PPI treatment had significantly higher index mortality compared to patients without PPI treatment (30.0% vs 11.1%, P = 0.003). After adjusting for comorbidities PPI remained an independent predictive factor with an OR of 2.56 (1.01-6.46, P = 0.036). CONCLUSIONS: PPI treatment is associated with higher index mortality in patients with pyogenic liver abscess. Therefore, critical evaluation of the indication for PPI treatment is particularly important in patients at high risk for pyogenic liver abscess.
引用
- Bettinger D, Martin D, Rieg S, et al. Treatment with proton pump inhibitors is associated with increased mortality in patients with pyogenic liver abscess. Aliment Pharmacol Ther. 2018. PMID: 29327781. doi:10.1111/apt.14512
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。